R. Parisi, D. Symmons, C. Griffiths, and D. M. Ashcroft, Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence, J Invest Dermatol, vol.133, issue.2, p.37785, 2013.

C. Griffiths, J. M. Van-der-walt, D. M. Ashcroft, C. Flohr, L. Naldi et al., The global state of psoriasis disease epidemiology: a workshop report, Br J Dermatol, vol.177, issue.1, p.47, 2017.

M. Richard, F. Corgibet, M. Beylot-barry, A. Barbaud, C. Bodemer et al., Sex-and ageadjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the « OBJECTIFS PEAU » study, J Eur Acad Dermatol Venereol JEADV, 2018.

A. B. Kimball, D. Gladman, J. M. Gelfand, K. Gordon, E. J. Horn et al., National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening, J Am Acad Dermatol, vol.58, issue.6, p.103142, 2008.

Y. Chen and J. Lyga, Brain-skin connection: stress, inflammation and skin aging, Inflamm Allergy Drug Targets, vol.13, issue.3, p.17790, 2014.

R. L. O'sullivan, G. Lipper, and E. A. Lerner, The neuro-immuno-cutaneous-endocrine network: relationship of mind and skin, Arch Dermatol, vol.134, issue.11, p.14315, 1998.

, Encyclo Méd Chir, Psychiatrie, p.2017

A. Zalli, O. Jovanova, W. Hoogendijk, H. Tiemeier, and L. A. Carvalho, Low-grade inflammation predicts persistence of depressive symptoms, Psychopharmacology (Berl), vol.233, issue.9, p.166978, 2016.

C. Debien, M. B. De-chouly-de-lenclave, P. Foutrein, and D. Bailly, Alpha-interferon and mental disorders, L'Encephale, vol.27, issue.4, p.30817, 2001.

M. B. Howren, D. M. Lamkin, and J. Suls, Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis, Psychosom Med, vol.71, issue.2, p.17186, 2009.

R. Haapakoski, J. Mathieu, K. P. Ebmeier, H. Alenius, and M. Kivimäki, Cumulative meta-analysis of interleukins 6 and 1?, tumour necrosis factor ? and C-reactive protein in patients with major depressive disorder, Brain Behav Immun, vol.49, p.20615, 2015.

J. Dahl, H. Ormstad, H. Aass, U. F. Malt, L. T. Bendz et al., The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery, Psychoneuroendocrinology, vol.45, p.7786, 2014.

J. Hannestad, N. Dellagioia, and M. Bloch, The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis, Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol, vol.36, issue.12, p.24529, 2011.

C. L. Raison, R. E. Rutherford, B. J. Woolwine, C. Shuo, P. Schettler et al., A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers, JAMA Psychiatry, vol.70, issue.1, p.3141, 2013.

R. Dantzer and . Cytokine, Sickness Behavior, and Depression, Neurol Clin, vol.24, issue.3, p.44160, 2006.

B. Ferreira, J. Abreu, J. Reis, and A. Figueiredo, Psoriasis and Associated Psychiatric Disorders, J Clin Aesthetic Dermatol, vol.9, issue.6, p.3643, 2016.

J. H. Saurat and D. Jullien, Dermatologie et infections sexuellement transmissibles, pp.269-280

M. Ammar, C. Souissi-bouchlaka, A. Gati, I. Zaraa, R. Bouhaha et al., Le psoriasis : physiopathologie et immunogénétique, Pathol Biol, vol.62, issue.1, p.1023, 2014.

M. A. Lowes, A. M. Bowcock, and J. G. Krueger, Pathogenesis and therapy of psoriasis, Nature, vol.445, p.866, 2007.

G. Girolomoni, R. Strohal, L. Puig, H. Bachelez, J. Barker et al., The role of IL-23 and the IL-23/TH17 immune axis in the pathogenesis and treatment of psoriasis, J Eur Acad Dermatol Venereol, vol.31, issue.10, p.161626, 2017.

. Psoriasis, Encyclo Méd Chir, Dermatologie

S. R. Feldman, Y. Zhao, L. Shi, and M. H. Tran, Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis, J Manag Care Spec Pharm, vol.21, issue.10, p.87488, 2015.
DOI : 10.18553/jmcp.2015.21.10.874

C. Pouplard, E. Brenaut, C. Horreau, T. Barnetche, L. Misery et al., Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies, J Eur Acad Dermatol Venereol JEADV, vol.27, issue.3, p.3646, 2013.

H. Yeung, J. Takeshita, N. N. Mehta, S. E. Kimmel, A. Ogdie et al., Psoriasis severity and the prevalence of major medical comorbidity: a population-based study, JAMA Dermatol, vol.149, issue.10, p.11739, 2013.

J. Takeshita, S. Grewal, S. M. Langan, N. N. Mehta, A. Ogdie et al., Psoriasis and comorbid diseases: Epidemiology, J Am Acad Dermatol, vol.76, issue.3, p.37790, 2017.
DOI : 10.1016/j.jaad.2016.07.064

URL : http://europepmc.org/articles/pmc5731650?pdf=render

E. J. Armstrong, C. T. Harskamp, and A. W. Armstrong, Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies, J Am Heart Assoc, vol.2, issue.2, p.62, 2013.

E. J. Samarasekera, J. M. Neilson, R. B. Warren, J. Parnham, and C. H. Smith, Incidence of Cardiovascular Disease in Individuals with Psoriasis: A Systematic Review and Meta-Analysis, J Invest Dermatol, vol.133, issue.10, p.23406, 2013.

T. M. Aberra, A. A. Joshi, J. B. Lerman, J. A. Rodante, A. K. Dahiya et al., Self-reported depression in psoriasis is associated with subclinical vascular diseases, Atherosclerosis, vol.251, p.21925, 2016.

F. Seligman and C. B. Nemeroff, The interface of depression and cardiovascular disease: therapeutic implications, Ann N Y Acad Sci, vol.1345, p.2535, 2015.

K. Lahlou-laforêt, Dépression et risque cardiovasculaire, J Mal Vasc, vol.37, issue.2, p.523, 2012.

A. W. Armstrong, C. T. Harskamp, and E. J. Armstrong, Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis, JAMA Dermatol, vol.149, issue.1, p.8491, 2013.

A. W. Armstrong, C. T. Harskamp, and E. J. Armstrong, The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies, J Hypertens, vol.31, issue.3, p.43342, 2013.

C. Ma, C. T. Harskamp, E. J. Armstrong, and A. W. Armstrong, The association between psoriasis and dyslipidaemia: a systematic review, Br J Dermatol, vol.168, issue.3, p.48695, 2013.

A. W. Armstrong, C. T. Harskamp, and E. J. Armstrong, The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies, Nutr Diabetes, vol.2, p.54, 2012.

R. B. Mansur, E. Brietzke, and R. S. Mcintyre, Is there a « metabolic-mood syndrome »? A review of the relationship between obesity and mood disorders, Neurosci Biobehav Rev, vol.52, p.89104, 2015.

J. K. Soczynska, S. H. Kennedy, H. O. Woldeyohannes, S. S. Liauw, M. Alsuwaidan et al., Mood disorders and obesity: understanding inflammation as a pathophysiological nexus, Neuromolecular Med, vol.13, issue.2, p.93116, 2011.

A. Ogdie and P. Weiss, The Epidemiology of Psoriatic Arthritis, Rheum Dis Clin North Am, vol.41, issue.4, p.54568, 2015.

R. T. Lewinson, I. A. Vallerand, M. W. Lowerison, L. M. Parsons, A. D. Frolkis et al., Depression Is Associated with an Increased Risk of Psoriatic Arthritis among Patients with Psoriasis: A PopulationBased Study, J Invest Dermatol, vol.137, issue.4, p.82835, 2017.

M. E. Husni, J. F. Merola, and S. Davin, The psychosocial burden of psoriatic arthritis, Semin Arthritis Rheum, vol.47, issue.3, p.35160, 2017.

J. Takeshita, S. Grewal, S. M. Langan, N. N. Mehta, A. Ogdie et al., Psoriasis and comorbid diseases: Implications for management, J Am Acad Dermatol, vol.76, issue.3, p.393403, 2017.

C. Roubille, V. Richer, T. Starnino, C. Mccourt, A. Mcfarlane et al., Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative, J Rheumatol, vol.42, issue.10, p.176780, 2015.

H. Tohid, D. Aleem, and C. Jackson, Major Depression and Psoriasis: A Psychodermatological Phenomenon, Skin Pharmacol Physiol, vol.29, issue.4, p.22030, 2016.

H. Selye, The stress of life-New focal point for understanding accidents, Ind Med Surg, vol.33, p.6215, 1964.

S. Lakshmy, S. Balasundaram, S. Sarkar, M. Audhya, and E. Subramaniam, A Cross-sectional Study of Prevalence and Implications of Depression and Anxiety in Psoriasis, Indian J Psychol Med, vol.37, issue.4, p.43440, 2015.

C. J. Connor, V. Liu, and J. G. Fiedorowicz, Exploring the Physiological Link between Psoriasis and Mood Disorders, Dermatol Res Pract, p.409637, 2015.

, Atlas de démographie médicale en France, Conseil national de l'ordre des médecins, 2017.

J. Koo, L. B. Marangell, M. Nakamura, A. Armstrong, C. Jeon et al., Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression, J Eur Acad Dermatol Venereol JEADV, vol.31, issue.12, 2017.

M. N. Nicholas, M. Gooderham, D. Psoriasis, and S. , Skin Ther Lett, vol.22, issue.3, p.14, 2017.

B. R. Ferreira, J. L. Pio-abreu, J. P. Reis, and A. Figueiredo, Analysis of the Prevalence of Mental Disorders in Psoriasis: The Relevance of Psychiatric Assessment in Dermatology, Psychiatr Danub, vol.29, issue.4, p.4016, 2017.

J. J. Wu, R. B. Penfold, P. Primatesta, T. K. Fox, C. Stewart et al., The risk of depression, suicidal ideation and suicide attempt in patients with psoriasis, psoriatic arthritis or ankylosing spondylitis, J Eur Acad Dermatol Venereol JEADV, vol.31, issue.7, p.116875, 2017.

S. K. Kurd, A. B. Troxel, P. Crits-christoph, and J. M. Gelfand, The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study, Arch Dermatol, vol.146, issue.8, p.8915, 2010.

E. A. Dowlatshahi, M. Wakkee, L. R. Arends, and T. Nijsten, The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis, J Invest Dermatol, vol.134, issue.6, p.154251, 2014.

R. C. Lamb, F. Matcham, M. A. Turner, L. Rayner, A. Simpson et al., Screening for anxiety and depression in people with psoriasis: a cross-sectional study in a tertiary referral setting, Br J Dermatol, vol.176, issue.4, p.102834, 2017.

E. D. Dommasch, T. Li, O. I. Okereke, Y. Li, A. A. Qureshi et al., Risk of depression in women with psoriasis: a cohort study, Br J Dermatol, vol.173, issue.4, p.97580, 2015.

A. Reich, K. M?drek, and J. C. Szepietowski, Interplay of Itch and Psyche in Psoriasis: An Update, Acta Derm Venereol, vol.96, issue.217, p.557, 2016.

M. A. Gupta, F. C. Simpson, and A. K. Gupta, Psoriasis and sleep disorders: A systematic review, Sleep Med Rev, vol.29, p.6375, 2016.

B. E. Strober, J. M. Sobell, K. C. Duffin, Y. Bao, A. Guérin et al., Sleep quality and other patientreported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial, Br J Dermatol, vol.167, issue.6, p.137481, 2012.

S. M. Consoli, S. Rolhion, C. Martin, K. Ruel, F. Cambazard et al., Low levels of emotional awareness predict a better response to dermatological treatment in patients with psoriasis, Dermatol Basel Switz, vol.212, issue.2, p.12836, 2006.

L. Misery, Depression and psoriasis, Ann Dermatol Venereol, vol.139, issue.2, pp.53-57, 2012.

C. Paul, G. Girolomoni, M. A. Radtke, F. Sampogna, P. Spuls et al., Impact of Alexithymia and Disease Characteristics on Work Productivity and Activity In Psoriasis Patients With Short Disease Duration: Epidepso Multicentre Study, Value Health J Int Soc Pharmacoeconomics Outcomes Res, vol.18, issue.7, pp.425-426, 2015.

D. G. Fortune, H. L. Richards, B. Kirby, K. Mcelhone, C. J. Main et al., Successful treatment of psoriasis improves psoriasis-specific but not more general aspects of patients' well-being, Br J Dermatol, vol.151, issue.6, p.121926, 2004.

S. Singh, C. Taylor, H. Kornmehl, and A. W. Armstrong, Psoriasis and suicidality: A systematic review and metaanalysis, J Am Acad Dermatol, vol.77, issue.3, pp.425-440, 2017.

A. B. Kimball, E. Q. Wu, A. Guérin, A. P. Yu, M. Tsaneva et al., Risks of developing psychiatric disorders in pediatric patients with psoriasis, J Am Acad Dermatol, vol.67, issue.4, pp.651-657, 2012.

A. W. Armstrong, C. T. Harskamp, J. S. Dhillon, and E. J. Armstrong, Psoriasis and smoking: a systematic review and meta-analysis, Br J Dermatol, vol.170, issue.2, p.30414, 2014.

P. Dupont, F. Thomas-jean, B. Pannier, and N. Danchin, Association entre tabagisme et état psychologique : impact de la consommation de tabac sur les suicides : la cohorte IPC, Rev Épidémiologie Santé Publique, vol.64, p.219, 2016.

E. Brenaut, C. Horreau, C. Pouplard, T. Barnetche, C. Paul et al., Alcohol consumption and psoriasis: a systematic literature review, J Eur Acad Dermatol Venereol JEADV, vol.27, issue.3, p.305, 2013.

A. Zink, M. Herrmann, T. Fischer, F. Lauffer, N. Garzorz-stark et al., Addiction: an underestimated problem in psoriasis health care, J Eur Acad Dermatol Venereol JEADV, vol.31, issue.8, p.130815, 2017.

P. Gorwood, Y. Lestrat, and M. Wohl, Comorbid addictions in bipolar disorder, L'Encephale, vol.34, pp.138-142, 2008.

M. S. Senra and A. Wollenberg, Psychodermatological aspects of atopic dermatitis, Br J Dermatol, vol.170, p.3843, 2014.

F. J. Dalgard, U. Gieler, L. Tomas-aragones, L. L. Poot, F. Jemec et al., The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries, J Invest Dermatol, vol.135, issue.4, p.98491, 2015.

A. Picardi, D. Abeni, C. F. Melchi, P. Puddu, and P. Pasquini, Psychiatric morbidity in dermatological outpatients: an issue to be recognized, Br J Dermatol, vol.143, issue.5, p.98391, 2000.

L. Misery, N. Feton-danou, and F. La-psychodermatologie-en, Ann Dermatol Vénéréologie, vol.135, issue.12, p.8635, 2008.

B. Strober, M. Gooderham, E. De-jong, A. B. Kimball, R. G. Langley et al., Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR), J Am Acad Dermatol, vol.78, issue.1, p.7080, 2018.

S. Tyring, A. Gottlieb, K. Papp, K. Gordon, C. Leonardi et al., Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial, Lancet Lond Engl, vol.367, issue.9504, p.2935, 2006.

R. G. Langley, S. R. Feldman, C. Han, B. Schenkel, P. Szapary et al., Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderateto-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial, J Am Acad Dermatol, vol.63, issue.3, p.45765, 2010.

S. R. Feldman, A. B. Gottlieb, M. Bala, Y. Wu, D. Eisenberg et al., Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis, Br J Dermatol, vol.159, issue.3, p.70410, 2008.

P. Fleming, C. Roubille, V. Richer, T. Starnino, C. Mccourt et al., Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review, J Eur Acad Dermatol Venereol JEADV, vol.29, issue.6, p.106370, 2015.

A. Menter, M. Augustin, J. Signorovitch, A. P. Yu, E. Q. Wu et al., The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial, J Am Acad Dermatol, vol.62, issue.5, p.8128, 2010.

C. Griffiths, M. Fava, A. H. Miller, J. Russell, S. G. Ball et al., Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies, Psychother Psychosom, vol.86, issue.5, p.2607, 2017.

T. Komori, A. Otsuka, Y. Honda, S. Kanameishi, T. Honda et al., Exacerbation of depression in a psoriatic arthritis patient possibly induced by secukinumab, Eur J Dermatol EJD, vol.26, issue.5, p.5067, 2016.

Y. Liu, R. Ho, and A. Mak, The role of interleukin (IL)-17 in anxiety and depression of patients with rheumatoid arthritis, Int J Rheum Dis, vol.15, issue.2, p.1837, 2012.

, Commission de la transparence, Brodalumab, 2018.

J. Hayes and J. Koo, Depression and acitretin: a true association or a class labeling?, J Drugs Dermatol JDD, vol.10, issue.4, p.40912, 2011.

M. B. Humble, Vitamin D, light and mental health, J Photochem Photobiol B, vol.101, issue.2, p.1429, 2010.
DOI : 10.1016/j.jphotobiol.2010.08.003

R. W. Lam, A. Buchanan, J. A. Mador, M. R. Corral, and R. A. Remick, The effects of ultraviolet-A wavelengths in light therapy for seasonal depression, J Affect Disord, vol.24, issue.4, p.23743, 1992.

J. Crowley, D. Thaçi, P. Joly, K. Peris, K. A. Papp et al., Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ?156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2), J Am Acad Dermatol, vol.77, issue.2, pp.310-317, 2017.

A. Otezla®, aprémilast) : nouvelles recommandations importantes concernant les idées et comportements suicidaires, 2016.